论文部分内容阅读
儿童急性淋巴细胞白血病(ALL)的治愈率接近70％,其中未愈的大部分病人与用药量不当有关,本研究发现甲氨喋呤(MTX)用药量、药物清除率与预后有关,同时对鬼臼噻吩甙(VM26)和阿糖胞苷(Ara-C)用量与疗效的关系进行了研究,结果如下。 病人188例是1988年10月至1991年11月新诊断的ALL,年龄4.3个月至18.8岁,诱导缓解的方案为强的松、长春新碱、左旋门冬酰胺酶、柔红霉素、VM26和Ara-C每4周为1疗程,共60周,每疗程的第2天和第22天鞘内注射MTX、氢化可的松、Ara-C至59周。高危型
The cure rate of childhood acute lymphoblastic leukemia (ALL) is close to 70%. Most of the unhealed patients are related to improper dosage. The study found that the dosage of methotrexate (MTX) and drug clearance rate are related to the prognosis. The relationship between the dosage of VM26 and Ara-C and the curative effect was studied. The results are as follows. A total of 188 patients were ALL newly diagnosed from October 1988 to November 1991, ranging in age from 4.3 months to 18.8 years. The predisposing regimens were Prednisone, Vincristine, L-Asparaginase, Daunorubicin, VM26 and Ara-C were given once every 4 weeks for 60 weeks. MTX, hydrocortisone and Ara-C were intrathecally injected for 59 weeks on days 2 and 22 of each course. High-risk type